GDRX
GoodRx Holdings, Inc.
+0.05 (+1.47%)3.44USD192K成交股數1.2B市值86.0本益比(近四季)1.5股價營收比-1.3%營收年增(近四季)2026-11-03下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 200M-1% | 194M-4% | 195M-0% | 196M-2% | 203M+3% | 203M+3% | 195M+8% | 201M+6% | 198M | 197M | 180M | 190M |
| 營業成本 | 21.0M | 20.2M | 17.5M | 13.4M | 13.4M | 13.4M | 11.7M | 11.9M | 12.5M | 15.2M | 18.7M | 16.3M |
| 毛利 | 179M-5% | 174M-8% | 177M-3% | 183M-3% | 190M+2% | 190M+4% | 184M+14% | 189M+9% | 185M | 181M | 161M | 173M |
| 毛利率 | 89.5% | 89.6% | 91.0% | 93.2% | 93.4% | 93.4% | 94.0% | 94.1% | 93.7% | 92.3% | 89.6% | 91.4% |
| 研發費用 | 26.7M | 30.2M | 28.9M | 31.0M | 29.9M | 31.1M | 30.1M | 30.9M | 31.0M | 32.0M | 39.6M | 31.3M |
| 銷售管理費用 | 24.8M | 26.8M | 23.9M | 32.0M | 28.4M | 29.6M | 25.6M | 27.6M | 41.1M | 30.4M | 35.3M | 30.2M |
| 營業利益 | 23.6M-12% | 14.0M-40% | 22.7M+11% | 14.6M-26% | 26.8M+263% | 23.4M-228% | 20.4M-153% | 19.9M+9% | 7.4M | −18.3M | −38.3M | 18.3M |
| 營業利益率 | 11.8% | 7.2% | 11.6% | 7.5% | 13.2% | 11.5% | 10.5% | 9.9% | 3.7% | -9.3% | -21.3% | 9.7% |
| 稅後淨利 | 8.5M-34% | 1.2M-89% | 5.4M+36% | 1.1M-83% | 12.8M-1373% | 11.1M-143% | 4.0M-110% | 6.7M-89% | −1.0M | −25.9M | −38.5M | 58.8M |
| 淨利率 | 4.3% | 0.6% | 2.8% | 0.6% | 6.3% | 5.4% | 2.0% | 3.3% | -0.5% | -13.2% | -21.4% | 31.0% |
| 稀釋 EPS | 0.02-50% | 0.00-100% | 0.02+100% | 0.00-100% | 0.04 | 0.03-150% | 0.01-111% | 0.02-86% | 0.00 | -0.06 | -0.09 | 0.14 |
| 稀釋股數 | 348M | 341M | 357M | 348M | 357M | 380M | 389M | 385M | 390M | 410M | 413M | 414M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 296M | 236M | 262M | 274M | 281M | 301M | 424M | 525M | 533M | 672M | 795M | 762M |
| 應收帳款 | 182M | 233M | 236M | 204M | 189M | 160M | 131M | 162M | 145M | 144M | 121M | 123M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 2.3B | 2.0B | 1.4B | 1.3B | 1.3B | 1.3B | 1.4B | 1.5B | 1.5B | 1.6B | 1.7B | 1.7B |
| 有息負債 | 482M | 482M | 483M | 484M | 485M | 486M | 488M | 646M | 647M | 648M | 649M | 650M |
| 總負債 | 1.7B | 1.4B | 788M | 725M | 676M | 641M | 658M | 806M | 823M | 827M | 827M | 797M |
| 股東權益 | 648M | 622M | 616M | 601M | 643M | 654M | 696M | 669M | 631M | 762M | 881M | 895M |
| 負債比 | 72.4% | 69.2% | 56.1% | 54.7% | 51.2% | 49.5% | 48.6% | 54.6% | 56.6% | 52.0% | 48.4% | 47.1% |
| 淨現金(現金 − 有息負債) | −185M | −247M | −221M | −211M | −204M | −185M | −63.8M | −121M | −113M | 24.6M | 146M | 112M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 11.8M+26% | – | – | – | 9.4M | – | – | 42.6M | – | – | – |
| 資本支出 | – | 1.1M | – | – | – | 142K | – | – | 407K | – | – | – |
| 自由現金流 | – | 10.7M+15% | – | – | – | 9.3M | – | – | 42.2M | – | – | – |
| 折舊攤銷 | 22.3M | 21.8M | 23.1M | 21.4M | 19.7M | 20.9M | 17.5M | 17.0M | 15.9M | 43.6M | 33.0M | 16.1M |
| 買回庫藏股 | – | 12.6M | – | – | – | 99.9M | – | – | 153M | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 5.5% | – | – | – | 4.6% | – | – | 21.3% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 797M
| Prescription Transactions Revenue | 544M | 68.3% | -5.8% |
|---|---|---|---|
| Pharma Direct Revenue | 151M | 19.0% | +41.2% |
| Subscription Revenue | 83.8M | 10.5% | -3.2% |
| Other Revenue | 17.7M | 2.2% | -15.8% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 797M | +0.6% | 30.4M | 3.8% | 0.09 | 164M |
| FY2024 | 792M | +5.6% | 16.4M | 2.1% | 0.04 | 183M |
| FY2023 | 750M | -2.1% | −8.9M | -1.2% | -0.02 | 137M |
| FY2022 | 767M | +2.8% | −32.8M | -4.3% | -0.08 | 143M |
| FY2021 | 745M | +35.4% | −25.3M | -3.4% | -0.06 | 174M |
| FY2020 | 551M | +41.9% | −294M | -53.3% | -1.07 | 111M |
| FY2019 | 388M | +55.6% | 66.0M | 17.0% | 0.18 | 81.9M |
| FY2018 | 250M | – | 43.8M | 17.6% | 0.12 | 44.4M |